BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors

首次发布于 2016 年 1 月 15 日

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

首次发布于 2022 年 6 月 24 日

Pelvic and Aortic-cava Lymphadenectomy Randomized for Ovarian Cancer

计划入组 450 人 · 首次发布于 2010 年 10 月 11 日

Ovarian Cancer (ErVimmune)

Oncoquest-Ovarian cancer

Ovarian Cancer(Dewpoint)

CENTER WEST CANCER

United States

Fujian Cancer Hospital (Fujian Cancer Institute, Fujian Cancer Prevention and Treatment Center)

China

Shaw Regional Cancer Center

United States

Avenzo's CDK2 Inhibitor AVZO-021 Shows Promising Activity in Breast and Ovarian Cancer Patients

Incyclix Bio Secures $5M Series B Extension to Advance CDK2 Inhibitor INX-315 in Resistant Breast and Ovarian Cancers

FDA Grants Fast Track Designation to Incyclix Bio's INX-315 for CCNE1-Amplified Platinum-Resistant Ovarian Cancer